Granules India’s Innovation: Research Centers Analyzed

Granules India has invested heavily in research and development with the launch of two new centers at the Technology Research Park of IIT Hyderabad. These centers will significantly boost Granules India’s ability to create new and improved medicines and skincare products. The company’s goal is to develop cutting-edge solutions for a range of industries.

Key Points

• Two new research centers opened at IIT Hyderabad.
• Focus on peptide development and particle engineering.
• Peptide center collaborates with a Swiss R&D team.
• Particle engineering center seeks new drug delivery systems.
• Increased internal capabilities for faster development cycles.
• Designed to create innovative products for regulated markets.

The first center, the Ascelis Center of Excellence for Peptide Development and Characterization, is part of Ascelis Peptides, Granules’ CDMO (Contract Development and Manufacturing Organization) arm. This facility will concentrate on developing peptides – tiny chains of amino acids – used in cosmetics, medicines, and other products. It’s the first time Granules has a dedicated lab in India for studying these peptides.

This new center is equipped to investigate how peptides are structured – from their basic shapes to more complex arrangements. By working with their research team in Switzerland, known as Senn Chemicals, Granules aims to build a stronger, more integrated approach to peptide development. This means they can respond more quickly to customer needs and improve the quality of their products.

The second center, the Granules Center of Excellence for Particle Engineering, will tackle the science of how medicines are made into powders. This includes studying different forms of materials and finding new ways to deliver drugs to the body, like creating ‘amorphous solid dispersions’.

This facility is designed to be a self-contained research hub, allowing Granules to quickly explore new ideas and bring them to market. It will provide the resources needed to pursue first-to-file opportunities, which means being the first to develop and market a new technology.

“Investing in these state-of-the-art facilities demonstrates Granules India’s commitment to innovation and its strategic ambition to become a global leader in specialized pharmaceutical ingredients.”